A One-Shot gene therapy could take on incurable blood cancer
NCT ID NCT06691685
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new gene therapy called ESO-T01 for people with relapsed or refractory multiple myeloma, a blood cancer that has stopped responding to standard treatments. ESO-T01 is given as an injection and works by instructing the body's own cells to become cancer-killing CAR-T cells that target a protein called BCMA on myeloma cells. The study aims to see if this approach is safe and tolerable, and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ESO-T01, a gene therapy that creates CAR-T cells inside the body to target BCMA on myeloma cells
- What this could lead to
- If successful, this approach could offer a new, more convenient treatment option for multiple myeloma that is resistant to standard therapies.
- What could go wrong
- This is an early, small trial focused on safety, so it is unknown if the treatment will be effective. There are risks of serious side effects like cytokine release syndrome and neurological toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- New PET tracer could sharpen diagnosis of blood cancers
- Web tool aims to empower rare cancer patients in genomic choices
- Diabetes drug metformin could boost myeloma treatment
- Experimental drug HDP-101 targets Hard-to-Treat myeloma